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Background: An adenovirus that expresses both interleukin (IL)-12 and granulocyte-macrophage
colony-stimulating-factor (GM-CSF) has been proven to be very effective in treating several tumors, but causes
serious normal tissue toxicities.
Methods: In this study, a novel adenoviral vector was constructed by placing the human GM-CSF gene under the
control of the CMV-IE promoter and human IL-12 gene under the control of heat shock protein 70B gene
promoter. Both hGM-CSF and hIL-12 expressions in virus-infected tumor cells were analyzed in vitro and in vivo
when underlying single or multiple rounds of hyperthermia.
Results: We observed constitutive high expression of human GM-CSF and heat-induced expression of human IL-12
after a single round of hyperthermia post viral infection. The heat-induced hIL-12 expression exhibited a pulse-like
pattern with a peak at 24 hrs followed by a decline 48 hrs post heat stress. Repeated heat treatment was more
effective in inducing hIL-12 expression than a one-time heat treatment. Interestedly, we also observed that
constitutive expression of hGM-CSF could be stimulated by heat stress in tested tumor cells.
Conclusion: Our study provided a novel strategy for combined gene therapy that allows constitutive expression of
a non-toxic gene such as GM-CSF and heat-induced expression of a toxic gene such as IL-12. In addition, our study
also showed that hyperthermia can be used to trigger gene expression in temporal and special manner.
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The unique ability of cancer to exploit the immune system
in order to promote tumor growth and suppress immune
response makes cancer therapy difficult. However, modu-
lation of the immune system should provide promising
results. Cytokines are a large family of intercellular signa-
ling peptides that function in the regulation of immune
response. Cytokine therapy has been reported to be an
effective strategy at inducing strong antitumor immune
response [1]. However, initial studies using systemic treat-
ment with recombinant cytokines produced discouraging
results due to dose-limiting toxicities [2]. Compared to* Correspondence: chuan.li@duke.edu; qhuang2012@yahoo.com
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reproduction in any medium, provided the orprotein therapy, gene therapy proved to be as efficient
while inducing less toxicity [3]. Among these cytokine-
based gene therapies, an adenovirus that expresses both
interleukin (IL)-12 and granulocyte-macrophage colony-
stimulating-factor (GM-CSF) has been proven to be very
effective in treating several tumors [4,5]. However, current
adenoviruses deliver constitutive IL-12 gene expression,
which causes serious normal tissue toxicity [6].
GM-CSF is a growth factor capable of enhancing antitu-
mor activity by activating dendritic cells (DCs) to improve
antigen presentation. GM-CSF can also activate macro-
phages and induce the release of tumor necrosis factor
(TNF) [7] to achieve an antitumor effect. In addition,
GM-CSF can indirectly stimulate T-cell activation via
interleukin-1 release [8]. However, increased cellular GM-
CSF expression also leads to counter-regulatory immune
responses to decrease the expansion of cytotoxic T cells. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IL-12 has been shown to exert potent immunostimulatory
effects on certain helper T cells as well as cytotoxic T lym-
phocytes (CTL) and natural killer (NK) cells [9]. Therefore,
the combined use of GM-CSF and IL-12 can counteract
the counter-regulatory role of GM-CSF on Tc and increase
the immune benefits of GM-CSF.
Human IL-12 is a disulfide-linked heterodimer com-
posed of 35 and 40 kDa subunits. Preclinical studies and
clinical trials of IL-12 gene therapy showed that this treat-
ment can induce remarkable anti-tumor response in
various tumors, including melanoma, sarcoma, and
adenocarcinoma [3]. However, both preclinical and clinical
tests revealed that IL-12 gene therapy can induce highly
toxic side effects [3]. This is because high constitutive
IL-12 expression increases IFN-γ production [10]. Thus,
IL-12 expression in gene therapy requires regulation.
However, the current adenovirus coexpressing GM-CSF
and IL-12 genes does not account for the regulation of
IL-12. Heat-based gene regulation is a ubiquitous stress
response to heat shock in mammalian cells. Based on this
feature, heat shock protein 70 promoter (hsp70B) has
been widely used in gene therapy to control gene expres-
sion [6]. The pharmacokinetics of GM-CSF and IL-12
production as well as possible interactions between consti-
tutive GM-CSF expression and heat-induced IL-12 expres-
sion should be investigated before clinical use. However,
there is the dilemma that IL-12 has a restrict species-
specificity. For example, human IL-12 shows no activity in
animal models and mouse IL-12 has no activity in human.
Although the efficacy and toxicity of sustained human IL-
12 expression cannot be evaluated in an animal model, the
expression pattern of the adenoviral vector must be first
tested in an animal model before entering clinical trials.
Currently, gene therapy with combined GM-CSF and
IL-12 has been established in several kinds of tumors
using adenovirus to express constitutive GM-CSF and IL-
12 levels. Although significant anti-tumor effect has been
observed, the level of GM-CSF or IL-12 is not regulatory
[4,11]. In this study, we first constructed a novel adeno-
viral vector that allowed constitutive expression of human
GM-CSF and heat-induced expression of human IL-12.
The pharmacokinetics of gene expression triggered by
hyperthermia was then tested in cell culture and in an ani-
mal model. Our study provided insights on tumor therapy
by combining gene therapy with hyperthermia.
Materials and methods
Cell culture
A549, a human non-small cell lung carcinoma cell line, and
Hep3B, a human hepatoma cell line, were purchased from
American Type Culture Collection. All cells were cultured
in RPMI 1640 with 10% fetal bovine serum, 100 units/mL
penicillin, and 100 μg/mL streptomycin at 37°C, 5% CO2.Adenovirus preparation
The adenovirus used to establish constitutively high
expression of human GM-CSF and heat-inducible ex-
pression of human IL-12 was constructed according to
established protocols [12] using commercially available
plasmids (Microbix, Toronto, Canada). To construct the
heat-inducible IL-12 expression cassette, cDNAs for
both the p40 and p35 subunits of human IL-12 were
inserted into the E1 region under control of the human
hsp70B gene promoter [13,14]. The p40 and p35 subu-
nits were connected using an internal ribosome entry
site sequence [15] so that both subunits could be tran-
scribed under the control of the same promoter. The
human GM-CSF expression cassette was constructed by
placing the human GM-CSF gene under the control of a
constitutively active CMV-IE promoter in the E1 region
[16] (see Figure 1). The completed adenovirus called
Adcmv-GMCSF-HSP-IL12 will establish constitutive
expression of human GM-CSF and heat-inducible ex-
pression of human IL-12. Large scale preparation of re-
combinant Adcmv-GMCSF-HSP-IL12 was accomplished
as previously described [17]. The control vector is an
adenovirus expressing GFP protein (Figure 1).
In vitro heating experiments
A549 and Hep3B cells were seeded in 24-well plates at a
density of 6 × 104 cells/well. After cells were cultured
for 24 hrs, 100, 500, and 1000vp (viral particles) of
Adcmv-hGMCSF-hsp-hIL12 virus were added into each
well. Twenty-four hours later, the culture medium was
replaced with 1 ml of fresh medium containing 2% FCS
and cells were heated in a 45°C water bath for 45 min.
Twenty-four hours later, the medium was collected for
hGM-CSF and hIL-12 measurement and replaced with
1 ml of fresh medium. Cells were heated again (45°C,
45 min) and the medium was collected 24 hrs post
heating.
In vivo heating experiments
Balb/C nude mice (BALB/c, nu/nu) weighing 20-22 g
were provided by the animal center of Shanghai Bio-
logical Science Institution and housed in rooms under
standard lighting conditions and temperature. Water
and food were provided ad libitum. All animal experi-
ments were conducted under an approved protocol from
Shanghai Jiaotong University and performed in accord-
ance with the animal care guidelines of the Chinese
Council. Hep3B tumors were introduced by subcutane-
ous injection of 1 × 107 Hep3B cells in 50 μL of PBS into
the right hind limbs of mice. When tumor size reached
1 cm in diameter, a total of 2 × 108 Adcmv-hGMCSF-
hsp-hIL12 was injected into tumor. Mice were divided
into 3 groups: non-heating group, one-time heating
group, and three-time heating group. In non-heating
Figure 1 A schematic diagram of adenovirus used in this study. HSP70-pro: heat shock protein 70 gene promoter; hIL12: human interleukin
12; CMV-pro: CMV promoter; hGMCSF: granulocyte-macrophage colony-stimulating-factor gene; EGFP: enhanced GFP.
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virus injection. In the one-time heating group, tumors
were heated once 24 hrs post virus injection and animals
were sacrificed on day 1, 2, 3 and 4 post heat treatment.
In three-time heating group, tumors were heated on day
1, 3, and 5 post virus injection and animals were sacri-
ficed on day 4, 5, 6, 7 post first heat treatment. Tumors
were heated to 42°C in a water bath for 40 min by
immersing the tumor-bearing leg in the water bath [18].
Tumor tissues were homogenized for hGM-CSF and
hIL-12 detection.
Detection of GM-CSF and IL-12 levels
The hGM-CSF and hIL-12 levels in cell culture medium
and tumor tissues homogenate were detected with humanFigure 2 hGM-CSF and hIL-12 expression in heat treated A549 and H
Adcmv-hGMCSF-hsp-hIL12 virus for 24 hrs and heated at 45°C for 45 min. T
measurement. A) hIL-12 expression under heating and no heating treatme
C) Relative hGM-CSF and hIL-12 expression in A549 cells. D) Relative hGM-C
repeated experiments.GM-CSF and human IL-12 ELISA kits (R&D Systems,
Minneapolis, MN).
Results
hGM-CSF and hIL-12 expression in Adcmv-hGMCSF-hsp-
hIL12 virus infected A549 and Hep3B cells
As shown in Figure 2, 1000, 500 and 100 viral particle per
cell (vp) infected cells exhibited significant increases in the
production of hGM-CSF and hIL-12 in A549 after heat
treatment (Figure 2A, B). In Hep3B cell medium, 1000 vp
of virus infection significantly increased hIL-12 (p=0.001)
and hGM-CSF (p = 0.008) production 24 hrs after heat
treatment. 500 vp and 100 vp virus infected cells also
exhibited significant increases in the production of hGM-
CSF and hIL-12 after heat treatment (Figure 2A, B). Heatep3B cells. A549 and Hep3B cells in 24-well plates were infected with
wenty-four hours late, medium was collected for hGM-CSF and hIL-12
nt. B) hGM-CSF expression under heating and no heating treatment.
SF and hIL-12 expression in Hep3B cells. HT: heating treatment. N = 5
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increases in hIL-12 production in 1000 vp and 500 vp
virus infected A549 cells (Figure 2C). In Hep3B cells, heat
treatment induced 6.13 ± 1.89 and 3.46 ± 0.36 fold
increases in cells infected with 1000 vp and 500 vp virus
respectively, whereas heat treatment induced 19.02 ± 4.95
fold increase in cells infected with 100 vp virus
(Figure 2D). In both A549 and Hep3B cells, hGM-CSF ex-
pression showed dependence on virus dosage. Although
hGM-CSF was driven by CMV promoter, hGM-CSF ex-
pression was increased 1.48 ± 0.08 fold in A549 cells and
2.81 ± 0.29 fold in HepB3 cells after heat treatment.
The effect of heat treatments on hGM-CSF and hIL-12
expression
As shown in Figure 3A in non-heated A549 cells, first heat
treatment significantly increased hIL-12 levels in A549
cells infected with 100 vp 500 vp, 1000 vp virus, respec-
tively, while the second heat treatment was more efficient
in increasing hIL-12 levels in A549 cells (p < 0.05 at all 3
viral dosages). In non-heat treated Hep3B cells, first heat
treatment significantly increased hIL-12 expressions in
Hep3B cells 24 hrs after first heat treatment. The second
heat treatment was also more efficient in increasing hIL-
12 levels in Hep3B (p < 0.05 at all 3 viral dosages). These
results suggest that hIL-12 expression is heat-inducible. In
contrast, first heat treatment significantly increased hGM-
CSF expression in A549 cells infected with 500 vp and
1000 vp virus in non-heat treated A549 cells shown in
Figure 3B; however, second heat treatment did not signi-
ficantly increase hGM-CSF expression in A549 cells
(p > 0.05). In non-heat treated Hep3B cells, first heat treat-
ment increased hGM-CSF levels in Hep3B cells but
showed no statistical difference (p > 0.05). After second
heat treatment, significant difference was observed in
Hep3B cells infected with 1000 vp virus. These results
suggest that heat treatment can increase hGM-CSF ex-
pression, but hGM-CSF expression is not heat-dependent.
We further compared the expression of hIL-12
(Figure 3C) and hGM-CSF (Figure 3D) in A549 and
Hep3B cells infected with the virus underlying heat
treatment for 24 hrs and no heat treatment for 24 and
48 hrs. Results showed that there were no significant dif-
ferences in hIL-12 levels between 24 and 48 hrs in both
A549 and Hep3B cells infected with 3 different viral
doses underlying no heat treatment, but a significant in-
crease in A549 and Hep3B cells was observed after 24
hrs of heat treatment. These results suggest that hIL-12
expression is heat-inducible, but not time-dependent. In
contrast, significant differences in hGM-CSF levels were
observed in A549 and Hep3B cells infected with 500 vp
and 1000 vp virus underlying no heat treatment for 24
and 48 hrs. In A549 cells, heat treatment for 24 hrs
increased hGM-CSF levels, but hGM-CSF levels wereactually lower than in non-heat treated A549 cells for 48
hrs. In Hep3B cells, heat treatment for 24 hrs increased
hGM-CSF levels, but hGM-CSF levels were equal to or
higher than in non-heat treated Hep3B cells for 48 hrs.
These results suggest that hGM-CSF expression is time-
dependent but not heat-dependent.
The effect of heat treatment on in vivo hGM-CSF and
hIL12 expression
As shown in Figure 4, virus infection produced consist-
ent hGM-CSF and hIL-12 expression under no heat
treatment. hGM-CSF expression was significantly higher
than hIL-12, but both reached their peak at 24 hrs after
virus infection and began to decline slowly at 48 hrs post
virus infection until day 7 of our observation. Under
heat treatment, hIL-12 and hGM-CSF expressions were
significantly increased and reached a peak at 24 hrs after
each heating and began to decline 48hrs after heating.
As shown in Figure 4A, intratumoral injection of adeno-
viral vectors led to lower IL-12 expression. The first heat
treatment elevated hIL-12 level from 2500 ± 506 pg/ml
(no HT) to 3966 ± 661 pg/ml (p = 0.207), but second heat
treatment induced 9.53 fold increase in hIL-12 expression
compared to no heat treatment (p = 0.034) and 4.1 fold in-
crease compared to first heat treatment (HT1) (p = 0.036).
Although the third heat treatment (HT3) was less effective
than the second heat treatment, hIL-12 level was still
higher in heat treated tumors than in non-heat treated
tumors on day 7 since first treatment (p = 0.039), suggest-
ing that multiple heat treatments could keep a constitu-
tively low hIL-12 expression with a peak-like expression at
24 hrs after heating.
As shown in Figure 4B, the expression of hGM-CSF was
controlled by CMV promoter; however, hGM-CSF expres-
sion in tumor tissues increased 2.04 fold (p = 0.009) after
first heat treatment compared to non-heat treated tumor
tissues (p = 0.013). The expression of hGM-CSF increased
in tumor tissues within 24 hours after 2nd (p = 0.002) and
third (p = 0.013) heat treatments. However, the peak con-
centrations of hCM-GSF after heating were similar, and
no significant difference was observed between first, sec-
ond, and third heating treatments.
Discussion
Combined gene delivery has been widely adopted in gene
therapy to increase therapeutic efficacy. However, some
gene products are very toxic to normal tissues, which limit
effective clinical application. To overcome this obstacle,
the expression of one or more genes in the combined de-
livery should be regulated. Gene therapy utilizing a com-
bination of IL-12 and GM-CSF has been previously
established [4,5]. In this strategy, GM-CSF is able to
stimulate proliferation, maturation, and function of anti-
gen representation cells, while IL-12 is able to enhance
Figure 3 The time dependence of hGM-CSF and hIL-12 expression in heat treated A549 and Hep3B cells. Cells were infected and heated
as described in Figure 2. Medium was collected at 24 and 48 hrs after heating treatment. A) hIL-12 expression in A549 and Hep3B cells.
B) hGM-CSF expression in A549 and Hep3b cells. C) Comparison of hIL-12 expression between cells heated for 24 hrs and cells without heating
for 24 and 48 hrs. D) Comparison of hGM-CSF expression between cells heated for 24 hrs and cells without heating for 24 and 48 hrs. N = 5
repeated experiments.
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phocytes, and inhibit angiogenesis [5,8]. Another benefit
of this strategy is that IL-12 can counteract the negative
regulation of GM-CSF on Tc cells [7]. However, high
toxicity was observed with this combination due to the
consistently high IL-12 expression. To overcome the high
toxicity, we constructed an adenovirus to constitutively
express human GM-CSF while controlling IL-12 expressionvia a heat-inducible promoter. After viral infection, heat
stress induced a pulse-like expression of hIL-12 and a high
constitutive expression of hGM-CSF in vitro and in vivo.
Consistent with previous reports, constitutive hIL-12
expression was very low in both the A549 and Hep3B
cells under no heating. Heat stress induced 15 to 19 fold
increases in hIL-12 expression in cultured cells, while it
induced a 16.9 fold increase in Hep3B tumor tissues
Figure 4 hGM-CSF and hIL-12 expression in Hep3B tumor
tissues. Adcmv-GMCSF-hsp-hIL12 was intratumorly injected. Tumors
were not heated, heated for 1 time, 2 time, and 3 times at 42°C for
40 min. Animals were sacrificed at different time point and tumor
tissues were homogenized for hGM-CSF and hIL12 detection. A) hIL-12
expression in tumor tissues. B) hGM-CSF expression in tumor tissues.
N = 5 mice per group.
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promoter is highly inducible with low background acti-
vity. Consistent with our previous findings, heat-induced
hIL-12 expression peaked at 24 hrs and began to decline
at 48 hrs post heat treatment [18]. This pattern can re-
duce the consistently high IL-12 expression-induced tox-
icity. In addition, we found that the second heat
treatment is more effective than the first heat treatment
in inducing hIL-12 expression, but the third heat treat-
ment is less effective than the second heat treatment.
The lower efficacy of the third heat treatment in indu-
cing gene expression may suggest that one injection of
non-replicating adenovirus can only support a limited
number of heat treatments that induce gene expression.
In addition, high virus dose could produce high hIL-12 ex-
pression under heat stress. However, low dose infectionproduced relatively higher amplification rate in hIL-12 ex-
pression due to the existence of low leak in hsp promoter
activity. This observation supports the idea that the virus
dose can be selected for clinical application. We acknow-
ledge that we didn’t test the temperature-dependent effect
of IL-12 expression and that is a weakness to this study.
However, previous studies demonstrated a temperature-
dependent effect in hsp70 promoter controlled gene ex-
pression [19,20]. The second weakness is that the activity
and toxicity of inducible human IL-12 cannot be tested in
the animal model because human IL-12 shows no activity
in animals and the nude mice used in this study are
immunodeficient.
In this study, the adenovirus was constructed with a
CMV-IE promoter to control human GM-CSF expression.
The CMV promoter should produce highly constitutive
hGM-CSF expression. However, heat treatment at 45°C
increased hGM-CSF expression by 1-1.5 folds in A549
cells and 2-3 folds in Hep3B cells. In addition, the in vivo
heating study revealed that although the first heat treat-
ment induced a 2-fold increase in hGM-CSF expression,
the second and third heat treatments didn’t increase
hGM-CSF expression as much as the first treatment. In
contrast, hGM-CSF expression was stable for 6 days after
first heat treatment and declined on day 7. This observa-
tion suggests that the heat-inducible hGM-CSF expression
is not heat-dependent but time-dependent. We also noted
that heat induction of hGM-CSF expression is more obvi-
ous in Hep3B cells than in A549 cells, suggesting cell type
dependence. Recently, the stimulating effect of heat stress
on CMV promoter activity has been studied [21,22]. Al-
though the possible mechanisms might be complex, a con-
siderable homology to the heat stress element core
consensus (GA–TCC) within 18 bp elements in IE enhan-
cer might be the most reasonable explanation [21,23].
Heat stress might regulate CMV-IE activity directly and
indirectly through heat-activated transcription factors.
Heat stress inducing various transcriptional factors, in-
cluding those activating the CMV-IE promoter, has been
reported [21,22]. Therefore, the cell type dependence
might reflect the high specificity of the signaling pathway
and transcription factors.
In this study, we established constitutive high expres-
sion of human GM-CSF and heat-induced expression of
human IL-12 with a single adenoviral vector. The heat-
induced hIL-12 expression has a pulse like shape with a
peak at 24 hrs post heat stress that is maintained for
24 hrs in tumor tissues. Repeated heat treatments are ef-
fective but limited by the clearance of non-replicating
adenovirus. Together with the low background activity
of hsp70 promoter, heat induced gene expression
enables a fairly strict control of gene expression, which
diminishes the cytotoxicity of toxic cytokines . We also
observed that the CMV-IE promoter driven constitutive
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heat stress in a cell type dependent manner. However,
the CMV-IE promoter activity cannot be regulated by
heat stress. Our study provided solid evidence for the
feasibility of heat-induced regulation of gene expression
in a combined gene delivery vector.
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